Bryan M. Reasons - 01 Jun 2024 Form 4 Insider Report for Aclaris Therapeutics, Inc. (ACRS)

Reporting relationship: Director
Issuer ticker: ACRS
Reported as of: 01 Jun 2024
Net transaction value: $0
SEC form: 4
Accepted by SEC: 04 Jun 2024, 16:30:22 UTC
Prior SEC filing: 08 Apr 2024
Next SEC filing: 02 Jan 2025
Source filing: View source filing
Reporting owner signature: /s/ Matthew Rothman, Attorney-in-Fact

Key filing fact

Bryan M. Reasons filed Form 4 for Aclaris Therapeutics, Inc. (ACRS) on 04 Jun 2024.

Key facts

This page summarizes Bryan M. Reasons's Form 4 filing for Aclaris Therapeutics, Inc. (ACRS).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 04 Jun 2024, 16:30.

Change

Previous filing in this sequence was filed on 08 Apr 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ACRS transaction

Common Stock

Options Exercise

Transaction value
Shares: +4,660
Change %: +19%
Price
Shares after: 28,732
Date: 01 Jun 2024
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ACRS transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value: $0
Shares: -4,660
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 01 Jun 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 4,660
Exercise price
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.

Footnote F2

The shares underlying these restricted stock units vested on June 1, 2024.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. to update or revoke optional consent for future visits. For more information, see our Privacy Policy .